Michael E. Williams

7.3k total citations
111 papers, 3.3k citations indexed

About

Michael E. Williams is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Michael E. Williams has authored 111 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pathology and Forensic Medicine, 50 papers in Genetics and 38 papers in Oncology. Recurrent topics in Michael E. Williams's work include Lymphoma Diagnosis and Treatment (53 papers), Chronic Lymphocytic Leukemia Research (46 papers) and Viral-associated cancers and disorders (12 papers). Michael E. Williams is often cited by papers focused on Lymphoma Diagnosis and Treatment (53 papers), Chronic Lymphocytic Leukemia Research (46 papers) and Viral-associated cancers and disorders (12 papers). Michael E. Williams collaborates with scholars based in United States, Canada and United Kingdom. Michael E. Williams's co-authors include Michael F. Jarvis, Geoffrey Burnstock, Steven H. Swerdlow, Ronald P. Taylor, Margaret A. Lindorfer, Paul V. Beum, Adam D. Kennedy, John Densmore, Brad S. Kahl and Charles E. Hess and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Physical review. B, Condensed matter.

In The Last Decade

Michael E. Williams

103 papers receiving 3.2k citations

Peers

Countries citing papers authored by Michael E. Williams

Since Specialization

Citations

This map shows the geographic impact of Michael E. Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Williams more than expected).

Fields of papers citing papers by Michael E. Williams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Williams. The network helps show where Michael E. Williams may publish in the future.

Co-authorship network of co-authors of Michael E. Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Williams. A scholar is included among the top collaborators of Michael E. Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Williams. Michael E. Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A retrospective observational study of rapid titration of venetoclax (VEN) in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). 2024 ·Journal of Clinical Oncology ·(unknown), Emily C. Ayers, Michael G. Douvas, (unknown), John Densmore, Michael E. Williams, Craig A. Portell	0
2	Accuracy differences in cannabis retailer information ascertained from webservices and government-maintained state registries across US states legalizing the sale of cannabis in 2019 2023 ·PubMed ·Michael E. Williams, (unknown), (unknown), (unknown), (unknown), (unknown), Danielle F. Haley	1
3	Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL 2021 ·Blood Advances ·Kallesh D. Jayappa, Vicki L. Gordon, Christopher G. Morris, Briana Wilson, (unknown), (unknown), (unknown), Krista M. Isaac, Shekhar Saha, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Michael J. Weber	13
4	Risk of Major Bleeding with Ibrutinib 2018 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Paul R. Kunk, Surabhi Palkimas, (unknown), Michael Devitt, Bethany J. Horton, Craig A. Portell, Michael E. Williams, Hillary S. Maitland	48
5	CAR-T Cell Therapy for Chronic Lymphocytic Leukemia 2017 ·Journal watch ·Michael E. Williams	1
6	Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL 2017 ·Blood Advances ·Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, (unknown), Julia Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber	81
7	Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) 2013 ·Blood ·Mark J. Axelrod, Zhishuo Ou, Liang Zhang, Vicki L. Gordon, (unknown), Archito T. Tamayo, R. Ford, Lan V. Pham, Michael J. Weber, Michael E. Williams, Michael Wang	5
8	Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models 2007 ·The Journal of Immunology ·Yongli Li, Michael E. Williams, John B. Cousar, Andrew W. Pawluczkowycz, Margaret A. Lindorfer, Ronald P. Taylor	50
9	Clonal Evolution in Chronic Lymphocytic Leukemia 2006 ·Journal watch ·Michael E. Williams	0
10	Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia 2006 ·The Journal of Immunology ·Michael E. Williams, John Densmore, Andrew W. Pawluczkowycz, Paul V. Beum, Adam D. Kennedy, Margaret A. Lindorfer, (unknown), (unknown), Ronald P. Taylor	124
11	The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes 2006 ·The Journal of Immunology ·Paul V. Beum, Adam D. Kennedy, Michael E. Williams, Margaret A. Lindorfer, Ronald P. Taylor	168
12	Biology and therapy of mantle cell lymphoma 2005 ·Current Opinion in Oncology ·Michael E. Williams, John Densmore	35
13	Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma 2005 ·Leukemia Research ·(unknown), Gwyn Bebb, Richard Klasa, Mukesh Chhanabhai, Valia S. Lestou, Douglas E. Horsman, Randy D. Gascoyne, Adrian Wiestner, Dana Masin, Marcel B. Bally, Michael E. Williams	27
14	Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia 2004 ·The Journal of Immunology ·Adam D. Kennedy, Paul V. Beum, Michael D. Solga, David J. DiLillo, Margaret A. Lindorfer, Charles E. Hess, John Densmore, Michael E. Williams, Ronald P. Taylor	276
15	From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades 2002 ·Human Pathology ·Steven H. Swerdlow, Michael E. Williams	103
16	Purines: from premise to promise 2000 ·Journal of the Autonomic Nervous System ·Michael E. Williams	9
17	Mantle cell lymphoma 2000 ·Current Treatment Options in Oncology ·John Densmore, Michael E. Williams	8
18	Recurrent epstein-barr virus-associated post-transplant lymphoproliferative disorder: Report of a patient with histologically similar but clonally distinct metachronous abdominal and brain lesions 1999 ·Human Pathology ·James W. Mandell, Margaret L. Gulley, Michael E. Williams, Mark H. Stoler	5
19	Paracortical Nodular T-Cell Lymphoma 1995 ·The American Journal of Surgical Pathology ·William R. Macon, Michael E. Williams, John P. Greer, John B. Cousar	23
20	In situ hybridization detection of cyclin Dl mRNA in centrocytic/mantle cell lymphoma 1995 ·Annals of Oncology ·Michael E. Williams, Guy E. Nichols, Steven H. Swerdlow, Mark H. Stoler	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact